OVAS vs. LQDA, AMPH, GPCR, DVAX, CALT, MNKD, PCRX, HROW, SYRE, and WVE
Should you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Liquidia (LQDA), Amphastar Pharmaceuticals (AMPH), Structure Therapeutics (GPCR), Dynavax Technologies (DVAX), Calliditas Therapeutics AB (publ) (CALT), MannKind (MNKD), Pacira BioSciences (PCRX), Harrow (HROW), Spyre Therapeutics (SYRE), and Wave Life Sciences (WVE). These companies are all part of the "medical" sector.
OvaScience vs. Its Competitors
OvaScience (NASDAQ:OVAS) and Liquidia Technologies (NASDAQ:LQDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.
Liquidia Technologies has a consensus target price of $26.89, indicating a potential upside of 102.78%. Given Liquidia Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Liquidia Technologies is more favorable than OvaScience.
OvaScience received 53 more outperform votes than Liquidia Technologies when rated by MarketBeat users. However, 69.72% of users gave Liquidia Technologies an outperform vote while only 63.87% of users gave OvaScience an outperform vote.
In the previous week, Liquidia Technologies had 6 more articles in the media than OvaScience. MarketBeat recorded 6 mentions for Liquidia Technologies and 0 mentions for OvaScience. Liquidia Technologies' average media sentiment score of 1.15 beat OvaScience's score of 0.00 indicating that Liquidia Technologies is being referred to more favorably in the news media.
22.5% of OvaScience shares are owned by institutional investors. Comparatively, 64.5% of Liquidia Technologies shares are owned by institutional investors. 7.4% of OvaScience shares are owned by company insiders. Comparatively, 30.1% of Liquidia Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
OvaScience has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500. Comparatively, Liquidia Technologies has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500.
Liquidia Technologies has a net margin of -903.80% compared to OvaScience's net margin of -10,128.37%. OvaScience's return on equity of -47.06% beat Liquidia Technologies' return on equity.
OvaScience has higher earnings, but lower revenue than Liquidia Technologies.
Summary
Liquidia Technologies beats OvaScience on 11 of the 17 factors compared between the two stocks.
Get OvaScience News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OvaScience Competitors List
Related Companies and Tools
This page (NASDAQ:OVAS) was last updated on 6/24/2025 by MarketBeat.com Staff
Buy OVAS Stock Free OVAS Stock Alerts